Contract Development Manufacturing Organizations Global Market Report 2024

Contract development manufacturing organizations refer to businesses that work on a contract basis with the pharmaceutical sector to provide medication development and manufacturing services. These businesses enable the pharmaceutical industry to outsource some of its operations, freeing up crucial time to concentrate on medication development and marketing.

The contract development manufacturing organizations are segmented by service into CMO, CRO; by product into small molecules, biologics and by end user into big pharma, small and mid-size pharma, generic pharmaceutical companies, and other end users.

The contract development manufacturing organizations market research report is one of a series of new reports that provides contract development manufacturing organizations market statistics, including contract development manufacturing organizations industry global market size, regional shares, competitors with a contract development manufacturing organizations market share, detailed contract development manufacturing organizations market segments, market trends and opportunities, and any further data you may need to thrive in the contract development manufacturing organizations industry. This contract development manufacturing organizations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The contract development manufacturing organizations market size has grown rapidly in recent years. It will grow from $222.5 billion in 2023 to $249.96 billion in 2024 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to growing complexity and specialization in drug development, increased demand for outsourcing in the pharmaceutical industry, cost containment and efficiency pressures, advancements in biotechnology and pharmaceutical research, globalization of the pharmaceutical and biopharmaceutical industries.

The contract development manufacturing organizations market size is expected to see rapid growth in the next few years. It will grow to $403.11 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to accelerated adoption of personalized medicine, rising demand for biologics and biosimilars, increased focus on research and development outsourcing, regulatory changes impacting pharmaceutical manufacturing. Major trends in the forecast period include technological advancements in manufacturing processes, integration of digital technologies in manufacturing processes, shift towards sustainable and environmentally friendly practices, rise of virtual and decentralized cdmo models, growing importance of data analytics in optimizing manufacturing operations.

The growing demand for pharmaceutical products due to the increase in chronic diseases and the geriatric population contributed to the growth of the contract development manufacturing organizations market. Rising chronic diseases and geriatric population has enabled pharmaceutical companies to manufacture biologics and biosimilars quickly, and most pharmaceutical firms have contracted contract production and manufacturing organizations operating on a contractual basis to handle and coordinate the company's tasks, operations and tests. For instance, according to the World Health Organization, the prevalence of chronic diseases rose is expected to grow 142.66 million by 2050 and the world's population of 60 years and older is projected to rise to 2 billion. Therefore, the growing demand for pharmaceutical products is projected to drive the growth of the contract development manufacturing organizations market .

The increasing number of clinical trials is expected to propel the growth of the contract development manufacturing organizations market going forward. Clinical trials for drug development are research studies conducted to evaluate the safety, efficacy, and potential side effects of a new drug or treatment in humans. Engaging in clinical trials can provide an additional revenue stream for CDMOs, expand services, can lead to long-term partnerships with pharmaceutical companies, enhance reputation, and can establish collaborative relationships. For instance, in May 2023, according to Xtalks, a Canada-based company specializing in providing life science webinars and virtual events, there are 452,604 clinical studies that have been registered on ClinicalTrials. gov as of May 17, 2023.64,838 studies out of the total number that have been registered are actively seeking participants which is an increase of 365,000 registered trials in 2021. Therefore, the increasing number of clinical trials is driving the growth of the contract development manufacturing organizations market .

The introduction of custom solutions is a key trend gaining popularity in the market for contract development and manufacturing organizations. Contract development and manufacturing companies focus on the implementation of custom technologies to address the unique needs of individual research applications. For instance, in October 2022, Aenova Holding GmbH, a Germany based pharmaceutical and healthcare contract manufacturing company, entered into a strategic partnership with Microcaps, a Switzerland based pharmaceutical company. Through this collaboration, both companies can develop and produce medicines, food supplements, and many other things more quickly and better. Microcaps will share their knowledge of cutting-edge, highly accurate microencapsulation and utilizing a patented technological platform, the technique allows for customized formulations, such as in release, protective coating, and texture.

Major companies operating in the contract development and manufacturing organizations market are focusing on innovative developments such as Lifera to drive revenues in their market. Lifera, a commercial-scale contract development and manufacturing organization (CDMO). For instance, in June 2023, Public Investment Fund (PIF), Saudi Arabia’s global investment organization launched Lifera. The production of vital biopharmaceutical goods, such as insulin, vaccinations, monoclonal antibodies, plasma treatments, cell and gene therapies, and cutting-edge small chemicals, will be Lifera's primary focus. To increase local capacity and support domestic manufacturing in this industry, the corporation will also form alliances with top domestic and foreign businesses and draw in specific investments. Driving formulation development, medication development, and manufacturing are some of Lifera's objectives .

In February 2022, Recipharm AB, a Sweden based pharmaceutical contract development and manufacturing company, acquired Arranta Bio for an undisclosed amount. Through this acquisition, Recipharm forms the basis of a plan to offer contract development and manufacturing services that are scientifically unique to innovative drug developers in the biologics industry, increases its capabilities in new biologics modalities, and will deliver a high level of diversification across many technologies and modalities. Arranta Bio is a US-based contract development and manufacturing organization (CDMO) that collaborates with businesses looking to develop and produce novel medicines and complicated biological pharmaceuticals.

Major companies operating in the in the contract development manufacturing organizations market report are Recipharm AB, AbbVie Contract Manufacturing LLC, Almac Group Limited, Baxter BioPharma Solutions LLC, Boehringer Ingelheim International GmbH, Catalent Pharma Solutions Inc., CMIC Holdings Co. Ltd., Covance Inc., Evotec SE, Famar Health Care Services Madrid SA, Jubilant Life Sciences Limited, Lonza Group Ltd., Patheon UK Limited, Pfizer CentreOne, The Lubrizol Corporation, Thermo Fisher Scientific Inc., Vetter Pharma International GmbH, Advanced BioScience Laboratories Inc., Adare Pharmaceuticals Inc., Aenova Holding GmbH, Ajinomoto Bio-Pharma Services, Albany Molecular Research Inc, Cambrex Corporation, CordenPharma International GmbH, EirGen Pharma Limited, Grand River Aseptic Manufacturing, Grifols Engineering SA, Hovione LLC, Metrics Contract Services, NextPharma Technologies Holding Limited, Nitto Avecia Pharma Services Inc., Piramal Pharma Solutions Inc., Siegfried Holding AG, Sterling Biotech Limited, Therapure Biopharma Inc., Velesco Pharmaceutical Services, WuXi PharmaTech (Cayman) Inc.

North America was the largest region in contract development manufacturing organizations market in 2023. The regions covered in the contract development manufacturing organizations market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the contract development manufacturing organizations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The contract development manufacturing organizations market includes revenues earned by entities by formulation, analytical services, blending, coating, and converting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.